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I N T R O D U C T I O N
Under conditions of increased circulatory demand, the 
activation of -adrenergic receptors leads to an increase 
in systolic force generation as well as an acceleration in 
the rates of rise and fall of the myocardial twitch. These 
changes in cardiac contractility are largely mediated by 
the activation of cAMP-dependent PKA, which catalyzes 
the phosphorylation of several Ca
2+-handling proteins; 
e.g.,  sarcolemmal  L-type  Ca
2+  channels,  phospholam-
ban, and the ryanodine-sensitive Ca
2+ release channels 
of the SR, as well as several sarcomeric proteins involved 
in the regulation of acto-myosin interactions; e.g., car-
diac troponin I (cTnI) and cardiac myosin–binding pro-
tein C (cMyBP-C) (for review see Bers, 2002; Lohse et al., 
2003; Layland et al., 2005). Importantly, PKA-catalyzed 
phosphorylation of cTnI and cMyBP-C has been shown 
to decrease the Ca
2+ sensitivity of force and to accelerate 
the kinetics of cross-bridge cycling in skinned myocardial 
preparations (Patel et al., 2001; Layland et al., 2005;   
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Stelzer et al., 2007). The respective contribution of these 
proteins, however, remains controversial despite signifi-
cant efforts to determine the effects of cTnI and cMyBP-C 
phosphorylation in isolation, given the importance of 
these proteins in regulating the contractile responses of 
myocardium to -adrenergic stimulation (Layland et al., 
2005; Sadayappan et al., 2005), the consequences of   
cTnI and cMyBP-C mutations in the pathogenesis of hy-
pertrophic cardiomyopathy (Redwood et al., 1999), as well   
as the implication that there is altered -adrenergic signal-
ing in the pathophysiology of cardiac hypertrophy, apop-
tosis, and end-stage heart failure (Lohse et al., 2003).
Recent studies have used transgenic animals to inves-
tigate the relationship of cTnI and cMyBP-C phosphory-
lation and the changes in contractile function that occur 
in response to PKA treatment. In the first of these stud-
ies, cTnI was stoichiometrically replaced with slow skeletal 
TnI (ssTnI) to investigate the functional consequences of 
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In skinned myocardium, cyclic AMP–dependent protein kinase A (PKA)-catalyzed phosphorylation of cardiac   
myosin–binding protein C (cMyBP-C) and cardiac troponin I (cTnI) is associated with a reduction in the Ca
2+ respon-
siveness of myofilaments and an acceleration in the kinetics of cross-bridge cycling, although the respective contri-
bution of these two proteins remains controversial. To further examine the relative roles that cTnI and cMyBP-C 
phosphorylation play in altering myocardial function, we determined the Ca
2+ sensitivity of force (pCa50) and the 
activation dependence of the rate of force redevelopment (ktr) in control and PKA-treated mouse myocardium 
(isolated in the presence of 2,3-butanedione monoxime) expressing: (a) phosphorylatable cTnI and cMyBP-C 
(wild type [WT]), (b) phosphorylatable cTnI on a cMyBP-C–null background (cMyBP-C
/), (c) nonphosphorylatable 
cTnI with serines
23/24/43/45 and threonine
144 mutated to alanines (cTnIAla5), and (d) nonphosphorylatable cTnI on 
a cMyBP-C–null background (cTnIAla5/cMyBP-C
/). Here, PKA treatment decreased pCa50 in WT, cTnIAla5, and 
cMyBP-C
/ myocardium by 0.13, 0.08, and 0.09 pCa units, respectively, but had no effect in cTnIAla5/cMyBP-C
/ 
myocardium. In WT and cTnIAla5 myocardium, PKA treatment also increased ktr at submaximal levels of activation; 
however, PKA treatment did not have an effect on ktr in cMyBP-C
/ or cTnIAla5/cMyBP-C
/ myocardium. In addi-
tion, reconstitution of cTnIAla5/cMyBP-C
/ myocardium with recombinant cMyBP-C restored the effects of PKA 
treatment on pCa50 and ktr reported in cTnIAla5 myocardium. Collectively, these results indicate that the attenuation 
in myofilament force response to PKA occurs as a result of both cTnI and cMyBP-C phosphorylation, and that the 
reduction in pCa50 mediated by cMyBP-C phosphorylation most likely arises from an accelerated cross-bridge cy-
cling kinetics partly as a result of an increased rate constant of cross-bridge detachment.
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phosphorylation of cMyBP-C, given that RLC phosphor-
ylation increases the Ca
2+ responsiveness of myofilaments 
(Olsson et al., 2004; Stelzer et al., 2006b; Colson et al., 
2010) in opposition to that of cMyBP-C phosphorylation. 
To reexamine the relative effects of PKA-mediated phos-
phorylation of cTnI and cMyBP-C on contractile prop-
erties in skinned myocardial preparations on a nominal 
phosphoprotein background, we used BDM-treated wild-
type (WT) and transgenic mouse myocardium express-
ing either nonphosphorylatable cTnI (cTnIAla5) or lacking 
the expression of cMyBP-C (cMyBP-C
/) to fully uncover 
the effects of cMyBP-C and/or cTnI phosphorylation 
on the Ca
2+ sensitivity of force (pCa50) and the activa-
tion dependence of the rate constant of force redevel-
opment (ktr). Our main results demonstrate that in the 
absence of basal RLC phosphorylation, both cMyBP-C 
and cTnI phosphorylation contribute to the reduction 
in Ca
2+ sensitivity mediated by PKA treatment in skinned 
myocardial preparations, whereas only cMyBP-C phos-
phorylation plays a prominent role in accelerating the 
kinetics of cross-bridge cycling. These observations were 
confirmed in control experiments in which mice ex-
pressing nonphosphorylatable cTnI on a cMyBP-C–null 
background (cTnIAla5/cMyBP-C
/) were used as an ex-
perimental platform after near stoichiometric reconsti-
tution of full-length recombinant cMyBP-C.
M AT E R I A L S   A N D   M E T H O D S
Transgenic mice
cTnIAla5 mice, in which five known phosphorylation sites on cTnI 
(serines
23/24/43/45 and threonine
144) were mutated to alanines, and 
cMyBP-C
/ mice were generated as described in detail by Pi et al. 
(2002) and Harris et al. (2002), respectively. cTnIAla5/cMyBP-C
/ 
mice were generated by breeding homozygous male and female 
cTnIAla5  mice  with  homozygous  male  and  female  cMyBP-C
/ 
mice. All procedures involving animal care and handling were   
reviewed and approved by the University of Wisconsin School of 
Medicine and Public Health Animal Care and Use Committee.
Solutions
Solution compositions were calculated using the computer pro-
gram of Fabiato (1988) and the stability constants (corrected to 
pH 7.0 and 22°C) listed by Godt and Lindley (1982). Unless other-
wise stated, all solutions contained (in mmol/L): 100 BES, 15 
creatine phosphate, 5 dithiothreitol, 1 free Mg
2+, and 4 MgATP. In 
addition, pCa 9.0 solution contained (in mmol/L) 7 EGTA and 
0.02 CaCl2, pCa 4.5 solution contained 7 EGTA and 7.01 CaCl2, 
and preactivating solution contained 0.07 EGTA. Ionic strength 
of all solutions was adjusted to 180 mmol/L using potassium pro-
pionate. A range of activating solutions containing different 
[Ca
2+]free was prepared by mixing pCa 9.0 and pCa 4.5 solutions.
Skinned myocardial preparations
Skinned ventricular myocardium was prepared according to the 
protocol described previously (Stelzer et al., 2006b). In brief, beat-
ing hearts were excised in vivo from anesthetized WT, cTnIAla5,   
cMyBP-C
/, and cTnIAla5/cMyBP-C
/ mice of either sex (6 mo 
old) and dissected in Ringer’s solution (in mmol/L: 120 NaCl,   
19 NaHCO3, 1.2 Na2HPO4, 1.2 MgSO4, 5 KCl, 1 CaCl2, and10 glu-
cose, pH 7.4; 22°C) preequilibrated with 95% O2/5% CO2. Basal 
removing the 31–amino acid N-terminal domain of cTnI 
normally targeted by PKA (serines
23/24). Here, Fentzke   
et al. (1999) and Kentish et al. (2001) showed that ex-
pression of ssTnI induced a significant leftward shift in 
the force–pCa relationship. However, PKA treatment 
had no significant effect on either Ca
2+ sensitivity of 
force or cross-bridge cycling kinetics, leading the au-
thors to conclude that phosphorylation of endogenous 
cTnI most likely plays a predominant role in mediating 
the  contractile  effects  of  PKA  treatment  in  skinned 
myocardial preparations. On the other hand, Stelzer   
et al. (2007) observed an accelerated rate of cross-bridge 
cycling  in  response  to  PKA  treatment  in  transgenic 
myocardium  expressing  non-PKA  phosphorylatable 
cTnI (cTnIAla2). Moreover, a small but statistically insig-
nificant trend toward a reduction in Ca
2+ sensitivity   
was also observed after PKA treatment, suggesting that 
cMyBP-C phosphorylation may also be involved in the 
regulation of myofilament Ca
2+ sensitivity. Interestingly, 
several investigators have also reported a similar trend 
toward decreased Ca
2+ sensitivity after PKA treatment   
in transgenic myocardium expressing either nonphos-
phorylatable cTnI (Pi et al., 2002) or phospho-mimetic 
cTnI (Yasuda et al., 2007). The variability in myofila-
ment force response to PKA and the resulting lack of 
statistically significant differences in these measure-
ments,  however,  have  prompted  these  investigators   
to  reach  the  same  conclusion  that  cMyBP-C  phos-
phorylation plays little role, if any, in the regulation of   
Ca
2+ sensitivity.
Recently, Bardswell et al. (2010) have reexamined   
the function of cMyBP-C phosphorylation in cTnIAla2  
myocardium previously treated with the -adrenergic re-
ceptor antagonist propranolol, showing a significant de-
sensitization of myofilament Ca
2+ sensitivity in response 
to PKA treatment. Although the introduction of pro-
pranolol  in  that  study  markedly  reduced  the  level  of 
cMyBP-C phosphorylation in cTnIAla2 myocardium and 
allowed the authors to observe an unprecedented signifi-
cant effect of PKA phosphorylation of cMyBP-C on Ca
2+ 
sensitivity of force, it remains to be determined whether 
additional reductions in the overall background of myo-
filament  protein  phosphorylation  affect  the  ability  of 
cMyBP-C phosphorylation to alter Ca
2+ sensitivity.
In the present study, we reduced the basal levels of 
myosin regulatory light chain (RLC) phosphorylation 
to uniformly low levels using 2,3-butanedione monox-
ime (BDM) as described previously (Olsson et al., 2004; 
Stelzer et al., 2006b) to allow for a more direct examina-
tion of the functional effects of cTnI and cMyBP-C 
phosphorylations  on  myofilament  function.  Because 
myocardial preparations used in mechanical studies are 
randomly chosen from ventricular wall homogenates, it 
is possible that inter-sample variations in the level of 
RLC phosphorylation preclude the reliable detection of 
decreased  Ca
2+  sensitivity  mediated  by  PKA-dependent   Chen et al. 617
placed on the stage of an inverted microscope (Olympus) fitted 
with a 40× objective and a CCTV camera (model WV-BL600; Pana-
sonic). Bitmap images were acquired using an AGP 4X/2X graphics 
card and associated software (ATI Technologies) to assess mean 
sarcomere length (SL) during the course of each experiment. 
Changes in force and motor position were sampled (16-bit resolu-
tion; model DAP5216a; Microstar Laboratories) at 2.0 kHz using 
SLControl software developed in the laboratory of Campbell and 
Moss (2003). At the start of each experiment, a skinned prepara-
tion was stretched to a mean SL of 2.2 µm and then transferred 
to preactivating solutions before being transferred into activating 
solutions of varying [Ca
2+]free (i.e., pCa 6.0–4.5) for simultaneous 
determination of Ca
2+-activated force and ktr. Once forces reached 
steady state in Ca
2+-activating solutions, the length of the prepara-
tion was rapidly slackened by 20% to induce detachment of my-
osin cross-bridges from actin, held at the slack length for 15 ms 
to allow for brief periods of unloaded shortening, and then re-
stretched back to the original length. Typical changes in forces 
recorded at pCa 4.5 and 9.0 during this protocol are illustrated in 
Fig. 1. After rapid decreases in muscle length, steady-state force 
abruptly fell to zero and remained at near zero until the prepara-
tion was restretched to its original length. Preparations were then 
transferred back into relaxing solution after forces recovered to 
near steady-state levels. Maximum levels of rundown in force and 
ktr measurements were <15 and 35%, respectively. At the conclu-
sion of each experiment, skinned preparations were solubilized 
in 10 µl of SDS sample buffer and stored at 80°C for subsequent 
protein analysis.
In experiments assessing the effects of PKA (catalytic subunit of 
bovine PKA; Sigma-Aldrich) on mechanical properties, skinned 
preparations were first incubated for 1 h (22°C) in pCa 9.0 solu-
tion containing 1 U PKA/µl\e. Mechanical properties were then 
measured as described above. In reconstitution experiments using 
purified recombinant cMyBP-C, skinned preparations were incu-
bated for 1 h (22°C) in pCa 9.0 solution containing 0.2 mg/ml 
cMyBP-C before the measurement of mechanical properties.
Analysis of myofibrillar protein expression, phosphorylation, 
and reconstitution
Phosphoproteins  and  myofibrillar  proteins  in  untreated  and  PKA-
treated WT, cTnIAla5, cMyBP-C
/, and cTnIAla5/cMyBP-C
/ myo-
cardium  were  examined  according  to  the  methods  described 
previously (Stelzer et al., 2006c), with minor modifications. Myo-
fibrillar proteins were quantified with the RC-DC protein assay (Bio-
Rad Laboratories), serially loaded onto 12.5 or 10% Tris-HCl Precast 
Criterion gels (Bio-Rad Laboratories), separated by SDS-PAGE, and 
stained with Pro-Q Diamond (Invitrogen) and SYPRO Ruby (Invit-
rogen) according to the manufacturer’s protocol. Phosphopro-
teins and myofibrillar proteins were then detected using UVP 
BioImaging System (UVP, LLC) and quantified with LaserPix soft-
ware (Bio-Rad Laboratories). The product of the area and mean 
optical density of each protein or phosphoprotein band of interest 
was then plotted versus protein load (µg), and a first-order linear 
regression was fitted to the data points to determine the slope of the 
relationship between optical density and protein load.
To assess the incorporation of recombinant cMyBP-C in recon-
stitution experiments, silver staining of SDS-PAGE gels was per-
formed as described previously (Stelzer et al., 2006b). In brief, 
gels were fixed in 50% methanol and 10% acetic acid and then 
(a) washed with distilled water, (b) incubated in 0.1% sodium 
thiosulfate solution for 90 s, (c) incubated in 0.09% silver nitrate 
solution for 20 min, and (d) imaged in developing solution con-
taining 0.0004% sodium thiosulfate, 2% potassium carbonate, and 
0.0068% formaldehyde until protein bands of interest became   
visible. The gels were then destained in 10% methanol and 10% 
acetic acid solution before imaging. Densitometric analysis was 
then performed using LaserPix software (Bio-Rad Laboratories), 
levels of RLC phosphorylation were reduced to uniformly low levels 
as described previously (Olsson et al., 2004; Stelzer et al., 2006b) 
by perfusing hemisected hearts with Ringer’s solution containing 
30 mmol/L BDM (30 min) before rapid freezing in liquid nitro-
gen. To obtain multicellular preparations (600–900 µm × 100–250 
µm), frozen ventricles were thawed and homogenized in ice-cold 
relaxing solution (in mmol/L: 100 KCl, 10 imidazole, 5 MgCl2,   
2 EGTA, and 4 ATP, pH 7.0) using a homogenizer (Polytron PT 10-
35; Kinematica, Inc.). Cellular homogenates were then centri-
fuged and washed with relaxing solution, resuspended in relaxing 
solution containing 250 µg/ml saponin and 1% Triton X-100 
(30 min), and washed with relaxing solution several times. The 
resulting skinned preparations were then used in mechanical ex-
periments or solubilized in SDS sample buffer for subsequent 
protein analysis.
Apparatus and experimental protocol
Mechanical measurements were performed at 22°C as described 
previously (Stelzer et al., 2006b). Skinned preparations with well-
defined edges were transferred into an experimental chamber 
containing relaxing solution and attached to the arms of a motor 
(model 350; Cambridge Technology) and force transducer (model 
403; Cambridge Technology). The chamber assembly was then 
Figure  1.  Experimental  protocol  for  simultaneous  determina-
tion of Ca
2+-activated force and the rate constant of force redevel-
opment (ktr) in skinned myocardium. The bottom panel depicts 
the changes in force recorded before, during, and after a step 
change in length (top panel) of skinned myocardium. Once iso-
metric force reached steady state in Ca
2+-activating solution (e.g.,   
pCa 4.5), muscle length was rapidly slackened by 20%. After 15 ms   
of  unloaded  shortening,  the  preparation  was  restretched  to 
its original length. Ca
2+-activated force at pCa 4.5 (P0) was deter-
mined by subtracting the resting force measured at pCa 9.0 from 
the total force generated at pCa 4.5. ktr was estimated by linear 
transformation of the half-time of force redevelopment after a 
rapid release–restretch maneuver.618 Cardiac myofilament phosphorylation and contraction
Data analysis
Cross-sectional areas of skinned preparations were calculated by 
assuming the preparations were cylindrical and by equating the 
width (measured from video images of the mounted prepara-
tions) to diameter. The difference between steady-state force and 
the force baseline obtained after a 20% slack step was taken as the 
total force for that [Ca
2+]free. Active force was then calculated by 
subtracting Ca
2+-independent force in pCa 9.0 solution from total 
force and normalizing to the cross-sectional area of the prepara-
tion. Each submaximal Ca
2+-activated force (P) was expressed as 
a fraction of the maximum Ca
2+-activated force (Po) generated by the 
preparations at pCa 4.5, i.e., P/Po. To determine the Ca
2+ sensitivity 
of isometric force (pCa50), the force–pCa data were fitted with the 
Hill equation: P/Po = [Ca
2+]
n/(k
n + [Ca
2+]
n)], where n is slope (Hill 
coefficient) and k is the Ca
2+ concentration required for half-maximal 
activation (pCa50). Apparent rate constants of force redevelopment 
(ktr) were determined by linear transformation of the half-time of 
force recovery (ktr = ln 0.5 × (t1/2)
1), as described previously (Patel 
et al., 2001). All data are presented as means ± SEM. Statistical analy-
ses of the data were done using an unpaired t test. P values <0.05 were 
taken as indicating significant differences.
and the ratio of the integrated optical density of the cMyBP-C 
band normalized to the integrated optical density of the corre-
sponding -actinin band was compared in reconstituted cTnIAla5/
cMyBP-C
/ preparations and cTnIAla5 preparations containing 
endogenous cMyBP-C.
Expression and purification of recombinant cMyBP-C
Purified recombinant cMyBP-C was generated as described previ-
ously (Ge et al., 2009). In brief, DNA sequence encoding full-
length cMyBP-C was PCR amplified from a clone containing 
full-length mouse cMyBP-C (provided by P.A. Powers, University 
of Wisconsin School of Public Health, Madison, WI) and cloned 
into pFastBac1 transfer plasmids (Invitrogen). The resulting vec-
tors encoding native cMyBP-C and an 11–amino acid N-terminal 
FLAG-tag epitope were then used for site-specific transposition of 
expression cassettes into bacmids. Baculovirus strains were pre-
pared according to the manufacturer’s instructions. High titer   
viral stocks were then used to infect Sf9 cell monolayers (2.2 × 10
7 
cells per 15-cm plate), and cells were collected 80–96 h after infec-
tion. Recombinant cMyBP-C was extracted and purified on anti-
FLAG M2 agarose columns (Sigma-Aldrich).
Figure 2.  Myofibrillar protein phosphorylation in untreated and PKA-treated WT, cTnIAla5, cMyBP-C
/, and cTnIAla5/cMyBP-C
/ 
skinned myocardium. (A) Representative 12.5% SDS-PAGE gel of myofibrillar proteins isolated from untreated () and PKA-treated (+) 
skinned myocardium and stained with SYPRO-Ruby to detect total protein and Pro-Q Diamond to detect phosphorylated proteins.   
(B) Slopes of proteins (top panel; n = 8) and phosphoproteins (bottom panel; n = 8) determined from regression analysis of plots of area × 
average optical density versus protein loaded (µg). Each bar represents the mean, and the error bar represents the SEM. *, P < 0.05.  Chen et al. 619
lation were undetectable in either Pro-Q Diamond–
stained SDS-PAGE gels or silver-stained two-dimensional 
gels (unpublished data). With the exception of desmin 
and TnT, PKA treatment elevated the phosphorylation 
status of both cMyBP-C and cTnI in WT myocardium, 
only cMyBP-C in cTnIAla5 myocardium, and only cTnI in 
cMyBP-C
/ myocardium (Fig. 2 B).
Ca
2+ sensitivity of force in untreated and PKA-treated  
WT and transgenic skinned myocardium
Table  I  summarizes  mechanical  properties  recorded 
from untreated and PKA-treated skinned preparations 
isolated from WT, cTnIAla5, cMyBP-C
/, and cTnIAla5/
cMyBP-C
/ myocardium. Under basal conditions, all 
four experimental groups generated similar amounts of 
maximum Ca
2+-activated force in pCa 4.5 solution. How-
ever,  cTnIAla5  and  cTnIAla5/cMyBP-C
/  preparations 
generated less Ca
2+-activated force at submaximal levels 
of activation. As a result, the force–pCa relationships es-
tablished in these preparations were shifted to the right 
(Fig. 3) of those established in WT controls and, most 
likely, reflected a functional consequence of the substi-
tution of serines
43/45 and/or threonine
144 for alanines in 
cTnI because a similar effect was also observed in recon-
stituted thin filaments incorporating these same muta-
tions (Noland et al., 1995).
In  response  to  PKA  treatment,  phosphorylation  of 
cTnI and cMyBP-C significantly reduced pCa50 in WT 
myocardium by 0.13 pCa units, whereas phosphoryla-
tion of cTnI alone produced a 0.09-pCa unit shift of the 
force–pCa curve to the right in cMyBP-C
/ myocar-
dium (Fig. 3). In the absence of cTnI phosphorylation, 
Online supplemental material
Fig. S1 shows representative force redevelopment tracings follow-
ing a mechanical slack–restretch maneuver in cTnIAla5/cMyBP-C
/ 
preparations before and after cMyBP-C reconstitution and after 
PKA  treatment  of  reconstituted  preparations.  It  is  available  at 
http://www.jgp.org/cgi/content/full/jgp.201010448/DC1.
R E S U LT S
PKA-catalyzed phosphorylation of myofibrillar proteins  
in WT and transgenic skinned myocardium
Fig. 2 A shows a representative SDS-PAGE gel illustrat-
ing the expression profiles of phosphorylated and non-
phosphorylated  myofibrillar  proteins  isolated  from   
WT, cTnIAla5, cMyBP-C
/, and cTnIAla5/cMyBP-C
/ myo-
cardium. Aside from the lack of cMyBP-C in cMyBP-C
/ 
and cTnIAla5/cMyBP-C
/ myocardium, the expression 
of myofibrillar proteins in cTnIAla5, cMyBP-C
/, and 
cTnIAla5/cMyBP-C
/ myocardium was similar to that 
observed in WT myocardium. Thus, neither ablation of 
cMyBP-C nor expression of nonphosphorylatable cTnI 
elicited any major changes in the expression pattern of 
myofibrillar proteins.
In control myocardial preparations, several myofibril-
lar proteins were found to exist in basally phosphorylated 
states in all four experimental groups. Specifically, the 
prominent phosphoproteins detected by Pro-Q Diamond 
staining included: cMyBP-C, desmin, TnT, and cTnI in 
WT myocardium; cMyBP-C, desmin, and TnT in cTnIAla5 
myocardium; desmin, TnT, and cTnI in cMyBP-C
/ myo-
cardium; and desmin and TnT in cTnIAla5/cMyBP-C
/ 
myocardium. However, the basal levels of RLC phosphory-
TA B L E   I
Effects of PKA treatment on mechanical properties in WT, cTnIAla5, cMyBP-C
/, and cTnIAla5/cMyBP-C
/ skinned myocardium
Treatment group Resting force
Maximum Ca
2+- 
activated force
Hill coefficient 
(nH)
Ca
2+ sensitivity of 
force 
(pCa50)
Maximum 
rate of force 
redevelopment
Minimum 
rate of force 
redevelopment
mN/mm
2 mN/mm
2 s
1 s
1
WT (n = 16)
() PKA (n = 8) 0.66 ± 0.07 14.43 ± 1.43 4.19 ± 0.15 5.82 ± 0.01 26.63 ± 0.88 2.22 ± 0.25
(+) PKA(n = 8) 0.54 ± 0.08 12.62 ± 1.37 4.21 ± 0.15 5.69 ± 0.01
a 27.98 ± 1.31 2.60 ± 0.12
cTnIAla5 (n = 16)
() PKA (n = 8) 0.89 ± 0.12 12.87 ± 1.03 5.03 ± 0.19
b 5.48 ± 0.01
b 22.00 ± 1.30
b 2.51 ± 0.24
(+) PKA (n = 8) 0.99 ± 0.20 15.07 ± 2.65 4.09 ± 0.18
a 5.40 ± 0.01
a 23.23 ± 1.06 3.95 ± 0.26
a
cMyBP-C
/ (n = 16)
() PKA (n = 8) 0.95 ± 0.12
b 15.68 ± 1.67 3.95 ± 0.08 5.83 ± 0.01 34.48 ± 1.96
b 3.66 ± 0.20
b
(+) PKA (n = 8) 0.67 ± 0.12 14.30 ± 1.21 3.59 ± 0.09
a 5.74 ± 0.01
a 34.09 ± 1.87 4.00 ± 0.11
cTnIAla5/cMyBP-C
/ (n = 16)
() PKA (n = 8) 1.23 ± 0.17
b 13.97 ± 1.40 4.25 ± 0.17 5.46 ± 0.01
b 35.39 ± 1.66
b 5.14 ± 0.43
b
(+) PKA (n = 8) 1.23 ± 0.27 16.8 ± 2.47 4.23 ± 0.23 5.45 ± 0.01 34.34 ± 2.26 5.35 ± 0.70
Data are means ± SEM. Resting force was measured at pCa 9.0. Maximum force and the apparent rate constant of force redevelopment (ktr) were measured 
at pCa 4.5. Minimum ktr was measured at 10% of maximum force. pCa50 and nH values were derived by fitting the force–pCa relationships to a Hill 
equation described in Materials and methods.
aSignificantly different from values recorded in untreated (PKA) skinned myocardial preparations.
bSignificantly different from values recorded in untreated (PKA) WT skinned myocardial preparations.620 Cardiac myofilament phosphorylation and contraction
untreated and PKA-treated WT and cTnIAla5 prepara-
tions (Table I). Furthermore, in the absence of cMyBP-C 
expression, no effects were observed on the ktr–force 
relationships in PKA-treated cMyBP-C
/ and cTnIAla5/
cMyBP-C
/ myocardium when compared with untreated 
controls. Thus, phosphorylation of cTnI by PKA treat-
ment in these preparations had no effect on the rate of 
force redevelopment.
Reconstitution of cTnIAla5/cMyBP-C
/ skinned myocardium 
with purified recombinant cMyBP-C
To further assess the functional effects of cMyBP-C phos-
phorylation on Ca
2+ sensitivity of force and the kinetics of 
cross-bridge cycling, skinned cTnIAla5/cMyBP-C
/ prepa-
rations were reconstituted with purified recombinant 
cMyBP-C (Fig. 5) and subjected to PKA treatment. Here, 
the readdition of near stoichiometric levels of cMyBP-C 
into cTnIAla5/cMyBP-C
/ preparations (0.98 ± 0.13 in 
reconstituted  cTnIAla5/cMyBP-C
/  preparations  vs. 
1.02 ± 0.09 in cTnIAla5 preparations) reduced ktr at all 
levels of activation (Fig. 6 B) but had no effect on pCa50 
(Fig. 6 A). In fact, reconstituted cTnIAla5/cMyBP-C
/ 
preparations were nearly indistinguishable from cTnIAla5 
preparations, confirming the functionality of the recom-
binant protein. In response to PKA treatment, cTnIAla5/
cMyBP-C
/ preparations reconstituted with cMyBP-C 
showed a significant reduction in Ca
2+ sensitivity (pCa50 = 
0.07) and a similar increase in ktr values reported in   
cTnIAla5 preparations (Fig. 6, C and D). These mechani-
cal properties are summarized in Table II.
PKA treatment of cTnIAla5 myocardium reduced pCa50 
to a similar degree as that observed in cMyBP-C
/ myo-
cardium (pCa50 = 0.08). However, these effects of PKA 
treatment on Ca
2+ sensitivity of force were completely 
abolished in cTnIAla5/cMyBP-C
/ myocardium.
Rate of force redevelopment in untreated and PKA-treated 
WT and transgenic skinned myocardium
Fig. 4 illustrates the activation dependence of ktr in un-
treated and PKA-treated WT and transgenic myocardium. 
Compared with WT preparations, cTnIAla5 preparations 
redeveloped submaximal forces at nearly the same rates. 
However, maximum ktr was significantly depressed in 
cTnIAla5 myocardium (26.63 ± 0.88 s
1 vs. 22.00 ± 1.30), 
most likely as a result of a minor shift in the expression 
of  myosin heavy chain to the slower  myosin heavy 
chain isoform (unpublished data), which has been shown 
to reduce the maximum ktr values in skinned myocar-
dial preparations (Locher et al., 2009). In cMyBP-C
/ 
and cTnIAla5/cMyBP-C
/ myocardium, however, ktr was 
dramatically increased at all levels of activation when 
compared with WT preparations, similar to results pub-
lished previously (Stelzer et al., 2007).
Compared with untreated control preparations, PKA-
treated WT and cTnIAla5 preparations redeveloped sub-
maximal forces at significantly faster rates. Hence, the 
curvilinear  ktr–force  relationships  in  PKA-treated  WT 
and  cTnIAla5  preparations  were  shifted  to  the  left  of 
those  established  in  untreated  control  myocardium. 
However, maximum ktr was not significantly different in 
Figure 3.  Effects of PKA treatment on Ca
2+ 
sensitivity of force in WT, cTnIAla5, cMyBP-
C
/, and cTnIAla5/cMyBP-C
/ skinned myo-
cardium.  Relative  isometric  steady-state  force   
(P/P0) measured as a function of log [Ca
2+]free 
(pCa) in untreated (; n = 8) and PKA-treated 
(; n = 8) preparations. Smooth lines were gen-
erated by fitting the mean data to a Hill equa-
tion, as described in Materials and methods. All 
data are plotted as means ± SEM.  Chen et al. 621
in the acceleration of cross-bridge cycling kinetics and the 
modulation of myofilament Ca
2+ sensitivity. Importantly, 
these findings implicate and underscore the role of thick 
filament accessory proteins in the regulation of cardiac 
contractility during the positive inotropic and lusitropic   
effects of -adrenergic stimulation in vivo.
Effect of PKA-dependent phosphorylation of cMyBP-C  
on Ca
2+ sensitivity of force
In WT skinned myocardium, PKA-catalyzed phosphory-
lation  of  cTnI  and  cMyBP-C  shifted  the  force–pCa   
D I S C U S S I O N
The primary focus of this study was to determine the con-
tribution of cMyBP-C phosphorylation to the changes in 
contractile function that occur in response to PKA treat-
ment. An important aspect of this study was the use of BDM 
treatments to reduce the basal levels of RLC phosphoryla-
tion to near zero to more accurately define the effects   
of cMyBP-C and/or cTnI phosphorylation on Ca
2+ sensitiv-
ity of force and the kinetics of force redevelopment in 
skinned myocardium. Results here provide conclusive evi-
dence to corroborate the role of cMyBP-C phosphorylation   
Figure  4.  Effects  of  PKA  treatment  on  the 
activation  dependence  of  the  rate  of  force 
redevelopment in WT, cTnIAla5, cMyBP-C
/, 
and  cTnIAla5/cMyBP-C
/  skinned  myocar-
dium.  The  apparent  rate  constant  of  force 
redevelopment (ktr) after a rapid release–re-
stretch  protocol  measured  as  a  function  of 
relative isometric steady-state force (P/P0) in 
untreated (; n = 8) and PKA-treated (; n = 8) 
preparations. All values are means ± SEM.
TA B L E   I I
Summary of mechanical properties in cTnIAla5/MyBP-C
/ skinned myocardium before (- cMyBP-C), after reconstitution with purified cMyBP-C  
(+ cMyBP-C), and after reconstitution with purified cMyBP-C and PKA treatment (+ cMyBP-C/+ PKA)
Treatment group Resting force
Maximum Ca
2+-
activated force
Hill coefficient 
(nH)
Ca
2+ sensitivity of 
force 
(pCa50)
Maximum rate of 
force redevelopment
Minimum rate of 
force redevelopment
mN/mm
2 mN/mm
2 s
1 s
1
cTnIAla5/cMyBP-C
/
() cMyBP-C  
(n = 7)
0.83 ± 0.15 14.70 ± 1.91 2.90 ± 0.08 5.49 ± 0.02 35.05 ± 2.52 2.28 ± 0.18
(+) cMyBP-C  
(n = 6)
1.26 ± 0.18 16.16 ± 1.08 3.28 ± 0.13
a 5.51 ± 0.01 15.37 ± 2.00
a 1.26 ± 0.22
a
(+) cMyBP-C (+) PKA  
(n = 6)
1.03 ± 0.29 12.68 ± 0.62 2.73 ± 0.09
b 5.44 ± 0.01
a,b 22.64 ± 2.50
a,b 3.48 ± 0.65
b
Data are means ± SE. Resting force was measured at pCa 9.0. Maximum force and the rate constant of force redevelopment (ktr) were measured at pCa 4.5. 
Minimum ktr was measured at 10% of maximum force. pCa50 and nH values were derived by fitting the force–pCa relationships to a Hill equation.
aSignificantly different from values recorded in cTnIAla5/cMyBP-C
/ skinned myocardial preparations (cMyBP-C).
bSignificantly different from values recorded in cTnIAla5/cMyBP-C
/ skinned myocardial preparations reconstituted with purified cMyBP-C (+cMyBP-C).622 Cardiac myofilament phosphorylation and contraction
more likely, removes the contribution of cMyBP-C phos-
phorylation to reduce pCa50 in cMyBP-C
/ myocar-
dium.  To  investigate  this  issue  further,  we  treated 
cTnIAla5 myocardium with PKA to isolate the effect of 
cMyBP-C phosphorylation on Ca
2+ sensitivity and ob-
served a similar rightward shift in the force–pCa rela-
tionship (pCa50 = 0.08). Further support for a role of 
cMyBP-C phosphorylation was provided by the lack of 
effect of PKA treatment in cTnIAla5/cMyBP-C
/ myo-
cardium, which was restored upon reconstitution of 
cTnIAla5/cMyBP-C
/ myocardium with purified recom-
binant  cMyBP-C.  Collectively,  these  results  strongly 
suggest that PKA-dependent phosphorylation of cMyBP-C 
and cTnI both contribute to the reduced Ca
2+ sensitiv-
ity of force and the positive lusitropic effects of -adren-
ergic stimulation.
Our finding that cMyBP-C phosphorylation contrib-
utes to the reduction in Ca
2+ sensitivity mediated by 
PKA treatment was not predicted by earlier studies 
(Fentzke et al., 1999; Kentish et al., 2001; Konhilas et al., 
2003) using ssTnI to elucidate the relative roles of cTnI 
and  cMyBP-C  phosphorylation.  This  implies  that  the 
cardiac isoform of TnI may be required for the phos-
phorylated species of cMyBP-C to influence the Ca
2+ 
sensitivity of force in mouse myocardium. Indeed, pre-
vious studies using nonphosphorylatable cTnI (Pi et al., 
2002) or phospho-mimetic cTnI (Yasuda et al., 2007) 
have reported a small but statistically insignificant de-
crease in Ca
2+ sensitivity of force mediated by PKA- 
dependent phosphorylation of cMyBP-C in skinned 
myocardial preparations. In light of our findings, it   
relationship to the right, decreasing the Ca
2+ sensitivity 
of force by 0.13 pCa units, in agreement with results 
published previously (Patel et al., 2001; Cazorla et al., 
2006; Stelzer et al., 2007; Colson et al., 2008). Although 
a desensitizing shift in the myofilament force response 
to Ca
2+ appears to be counterproductive in enhancing 
the inotropic state of -adrenergic stimulation, this   
effect of PKA phosphorylation is thought to improve the 
relaxation of myocardium during increased heart rates 
to allow for adequate ventricular filling and, in turn, 
proper stroke volume and an appropriate level of cardiac 
output. The ability of myofilament proteins to enter a 
desensitized state in the presence of activator Ca
2+, how-
ever, has primarily been attributed to the phosphoryla-
tion of cTnI by PKA, which has been shown to weaken 
the interaction of the N-terminal domains of cTnI and 
cTnC (Ward et al., 2004) and to reduce the binding affin-
ity of cTnC for Ca
2+ (Robertson et al., 1982). In this way, 
PKA-catalyzed phosphorylation of cTnI is thought to 
enhance  the  relaxation  of  myocardium,  primarily  by 
limiting the activation of cardiac thin filaments and re-
ducing the number of sites available on actin for strong-
binding cross-bridges to form and generate force.
In cMyBP-C
/ myocardium, PKA treatment decreased 
the Ca
2+ sensitivity of force by 0.09 pCa units, indicating 
that cTnI phosphorylation had a lesser effect on myofil-
ament Ca
2+ sensitivity than simultaneous phosphoryla-
tion of cMyBP-C and cTnI in WT myocardium. This 
finding is consistent with the earlier results of Cazorla 
et al. (2006) and suggests that the absence of cMyBP-C 
either inhibits the ability of cTnI to decrease pCa50 or, 
Figure 5.  Reconstitution of cTnIAla5/cMyBP-C
/ skinned   
myocardium  with  purified  recombinant  cMyBP-C.   
Representative  silver-stained  10%  SDS-PAGE  gel  of   
cTnIAla5 (lane 1) and cTnIAla5/cMyBP-C
/ preparations 
before cMyBP-C reconstitution (lane 2), after cMyBP-C 
reconstitution (lane 3), and after PKA treatment of 
reconstituted preparations (lane 4). Lane 5 shows the 
purified recombinant cMyBP-C protein expressed in 
baculovirus-infected Sf9 cells.  Chen et al. 623
of PKA treatment was observed in cTnIAla5 myocardium 
expressing phosphorylatable cMyBP-C but was absent in 
cMyBP-C
/  myocardium.  These  results  indicate  that 
the acceleration in force redevelopment at submaximal 
[Ca
2+]free in skinned myocardial preparations after PKA 
treatment is most likely a result of the phosphorylation 
of  cMyBP-C.  In  addition,  reconstitution  of  cTnIAla5/
cMyBP-C
/ preparations with recombinant cMyBP-C 
restored the values of ktr to baseline and rendered the 
preparations sensitive to the effect of PKA treatment;   
i.e., phosphorylation of reconstituted cMyBP-C recapitu-
lated the increase in ktr values reported in cTnIAla5 myocar-
dium that was otherwise absent in cTnIAla5/cMyBP-C
/ 
myocardium. This acceleratory effect of cMyBP-C phos-
phorylation on the kinetics of force redevelopment at 
submaximal levels of activation has been proposed to 
involve several potential mechanisms (Stelzer et al., 
2006c, 2007; Colson et al., 2008), including an increased 
probability of cross-bridge binding to actin, which would 
reduce the amount of time taken to cooperatively recruit 
cross-bridges into force-generating states, as well as an 
accelerated rate of cross-bridge cycling.
The possibility remains that cMyBP-C ablation may 
preclude the ability of cTnI phosphorylation to alter 
cross-bridge cycling kinetics in response to PKA treat-
ment. Hence, future studies must examine the role of 
cTnI phosphorylation in the context of non-PKA phos-
phorylatable cMyBP-C to conclusively rule out any con-
tributions of cTnI phosphorylation to the acceleration 
appears that the lack of statistical significance in these 
studies reflects an underlying variability in the level of 
RLC  phosphorylation  because  near  removal  of  RLC 
phosphorylation  markedly  reduced  the  variability  in 
myofilament force response to PKA treatment, allowing 
us to observe a statistically significant effect of cMyBP-C 
phosphorylation on Ca
2+ sensitivity.
Effect of PKA-dependent phosphorylation of cMyBP-C  
on the rate of force redevelopment
In skinned myocardium, there is compelling evidence 
to suggest that PKA-mediated phosphorylation of myo-
filament proteins also accelerates the kinetics of cross-
bridge cycling, as indicated by an increase in unloaded 
shortening  velocity  (Strang  et  al.,1994),  accelerated 
rates of force redevelopment (Patel et al., 2001; Stelzer 
et al., 2006c, 2007), and force relaxation (Zhang et al., 
1995; Kentish et al., 2001) and faster rates of force   
decay and delayed force redevelopment after stretch acti-
vation (Stelzer et al., 2006c). This effect of PKA treatment, 
however, is somewhat controversial because several inves-
tigators have reported no effect on myofibrillar ATPase 
activity (de Tombe and Stienen, 1995), unloaded short-
ening velocity (Hofmann and Lange, 1994; Janssen and 
de Tombe, 1997), or rate of force relaxation (Johns et al., 
1997). In this study, we found that PKA treatment accel-
erated the rate of force redevelopment at submaximal 
levels of activation in WT myocardium when compared 
with untreated WT controls. Moreover, a similar effect 
Figure  6.  Effects of cMyBP-C reconsti-
tution and PKA treatment in cTnIAla5/ 
cMyBP-C
/  skinned  myocardium. 
Force–pCa (A) and ktr–force (B) relation-
ships  in  cTnIAla5/cMyBP-C
/  prepa-
rations  before  (;  n  =  7)  and  after 
reconstitution (; n = 6) with cMyBP-C. 
Force–pCa (C) and ktr–force (D) rela-
tionships  in  cMyBP-C–reconstituted 
cTnIAla5/cMyBP-C
/  preparations   
before (; n = 6) and after (; n = 6) 
PKA treatment. All data are plotted as 
means ± SEM.624 Cardiac myofilament phosphorylation and contraction
could possibly reflect an underlying acceleration in gapp, 
such a mechanism could potentially account for the at-
tenuation in force generation at submaximal levels of 
[Ca
2+]free in WT and cTnIAla5 skinned myocardium after 
PKA treatment. This propounded acceleration in gapp 
after cMyBP-C phosphorylation, however, was not ap-
parent in the minimum value of ktr reported here in PKA-
treated WT skinned myocardium (Table I), although a 
statistically significance acceleration in minimum ktr was 
observed in PKA-treated cTnIAla5 skinned myocardium 
and PKA-treated cTnIAla5/cMyBP-C
/ skinned myocar-
dium reconstituted with cMyBP-C (Table II). Thus, addi-
tional studies aimed at directly ascertaining the value of 
gapp in response to PKA treatment are needed to validate 
the mechanism of cMyBP-C phosphorylation–mediated 
desensitization of myofilament Ca
2+ sensitivity. Lastly, al-
though it is also possible that cMyBP-C phosphorylation 
may decrease Ca
2+ sensitivity of force by reducing the 
number of cycling cross-bridges or the amount of force 
generated per cross-bridge, these alternatives appear less 
likely, given that maximum force generated at pCa 4.5 is 
unaltered by PKA treatment.
Presently, it is unclear how PKA-mediated phosphory-
lation of cMyBP-C enhances the rate of cross-bridge   
detachment.  One  possible  mechanism  may  be  that 
cMyBP-C  phosphorylation  increases  the  flexibility  or 
compliance of myosin cross-bridges, thereby potentially 
reducing the stability of cross-bridges bound to actin 
during active force development (Stelzer et al., 2006c,   
2007) and possibly enhancing the strain-dependent   
detachment  of  force-generating  cross-bridges.  Under 
normal conditions, the N-terminal cMyBP-C motif of 
cMyBP-C interacts with the subfragment 2 (S2) domain 
of myosin near the level arm domain of the myosin head 
(Gruen and Gautel, 1999). This interaction is thought 
to limit the availability of myosin cross-bridges for actin, 
possibly by tethering the heads of myosin cross-bridges 
closer to the thick filament backbone (Hofmann et al., 
1991), although it is also probable that such a mecha-
nism could potentially stabilize the structural integrity 
of the neck-hinge region of myosin, thereby affecting 
the transmission of force between cycling cross-bridges 
and actin. Recently, Nyland et al. (2009) have reported 
a reduction in the flexural rigidity of thick filaments   
in the absence of cMyBP-C, attributing the ability of 
cMyBP-C to stiffen the thick filament to its binding to 
myosin S2. Based on the putative interaction of cMyBP-C 
with myosin, we propose that the removal of the S2 inter-
action after PKA phosphorylation (Gruen et al., 1999)   
potentially destabilizes the hinge region of myosin in addi-
tion to moving the heads closer to actin (Colson et al., 
2008), causing untethered cross-bridges to become more 
flexible and to attach at a faster rate but ultimately unable 
to  remain  strongly  bound  to  actin  in  force-generating 
states.  As  a  result,  cross-bridges  would  detach  at  a 
faster rate, reducing the amount of force generated at   
in cross-bridge cycling, although previous studies using 
transgenic expression of nonphosphorylatable cMyBP-C 
at 74% on a cMyBP-C–null background have demon-
strated no effect on the rate constants of force relaxation 
and delayed force development in stretch activation ex-
periments after PKA treatment (Tong et al., 2008). Al-
though several investigators have posited a role for cTnI 
phosphorylation in the acceleration of cross-bridge kinet-
ics (Fentzke et al., 1999; Kentish et al., 2001; Turnbull   
et al., 2002), these studies do not demonstrate a direct 
effect of cTnI phosphorylation on cross-bridge cycling 
or an effect of cTnI phosphorylation in the absence of 
cMyBP-C phosphorylation. On the other hand, previous 
biochemical studies by Robertson et al. (1982) have dem-
onstrated a faster rate of Ca
2+ dissociation from cTnC in 
response to PKA-dependent phosphorylation of cTnI. 
Although this effect most likely contributes to the posi-
tive lusitropic effects of -adrenergic stimulation, pre-
sumably by amplifying the effects of phospholamban 
phosphorylation on sarco/endoplasmic reticular Ca
2+ 
ATPase reuptake of Ca
2+ into the SR, it remains to be 
determined whether phosphorylation of cTnI has any 
direct effects on the dynamics of cross-bridge cycling.
Possible mechanisms of cMyBP-C phosphorylation–
mediated attenuation of Ca
2+ sensitivity of force
Because an important functional outcome of cMyBP-C 
phosphorylation (in this study and others; Stelzer et al., 
2006c, 2007) is an acceleration of cross-bride cycling ki-
netics at submaximal levels of activation, it is reasonable 
to assume that such a mechanism could also account for 
a decrease in Ca
2+ sensitivity of force. Indeed, an over-
all acceleration in the rate of cross-bridge cycling could 
reflect an underlying acceleration in the rate of cross-
bridge  detachment  from  actin,  thereby  reducing  the 
amount of time cycling cross-bridges spend in the force-
generating state. Interestingly, Colson et al. (2008) have 
shown that PKA-mediated phosphorylation of cMyBP-C   
radially displaces the heads of myosin cross-bridges 
closer to actin, suggesting that the faster rate of force 
redevelopment is most likely a result of a faster rate of 
cross-bridge attachment. Assuming that cMyBP-C phos-
phorylation only accelerates the attachment and transi-
tion of weakly bound cross-bridges into strongly bound 
force-generating states, such a mechanism would be ex-
pected to lead to an increase in Ca
2+ sensitivity of force 
and oppose the reduction in Ca
2+ sensitivity mediated by 
cTnI phosphorylation. Therefore, in light of our data, 
we propose that cMyBP-C phosphorylation speeds up 
both the kinetics of cross-bridge attachment (fapp) and 
detachment (gapp), such that the acceleration in gapp ex-
ceeds that of fapp, leading to a reduced fraction of cycling 
cross-bridges in the force-generating state (i.e., reduced 
fapp/(fapp + gapp)) . Given that cMyBP-C phosphorylation 
has been shown to accelerate the kinetics of force de-
cay after stretch activation (Stelzer et al., 2006c), which   Chen et al. 625
phosphorylation accelerates the kinetics of cross-bridge 
cycling, most likely by inducing a disproportionate in-
crease in the rate constant of cross-bridge detachment, 
which would not only accelerate the rate of force devel-
opment but also allow the contractile apparatus to relax 
at a faster rate despite elevated levels of cytosolic [Ca
2+]free. 
In conjunction with the PKA effects of cTnI phosphory-
lation on myofilament Ca
2+ sensitivity and relaxation   
kinetics in vivo, these targeted modifications act to 
fine-tune the mechanical properties of the contractile 
apparatus in response to PKA-mediated changes in Ca
2+ 
handling, and enable the contractile apparatus to expe-
dite the rate of force development and relaxation dur-
ing -adrenergic stimulation.
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submaximal levels of [Ca
2+]free and thereby reducing the 
Ca
2+ sensitivity of force. These mechanisms, however, have 
yet to be substantiated and require further investigation.
It is important to note here that although phosphory-
lation and ablation of endogenous cMyBP-C elicit simi-
lar effects on cross-bridge disposition (Colson et al., 2007, 
2008) and cycling kinetics (Korte et al., 2005; Stelzer et al., 
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